Transgenic Cyclin E Triggers Dysplasia and Multiple Pulmonary Adenocarcinomas by Ma, Yan et al.
Dartmouth College 
Dartmouth Digital Commons 
Open Dartmouth: Published works by 
Dartmouth faculty Faculty Work 
3-6-2007 












See next page for additional authors Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa 
 Part of the Medical Genetics Commons, Medical Pathology Commons, Neoplasms Commons, and the 
Respiratory System Commons 
Dartmouth Digital Commons Citation 
Ma, Yan; Fiering, Steven; Black, Candice; Liu, Xi; Yuan, Ziqiang; Memoli, Vincent A.; Robbins, David J.; 
Bentley, Heather A.; Tsongalis, Gregory J.; Demidenko, Eugene; Freemantle, Sarah J.; and Dmitrovsky, 
Ethan, "Transgenic Cyclin E Triggers Dysplasia and Multiple Pulmonary Adenocarcinomas" (2007). Open 
Dartmouth: Published works by Dartmouth faculty. 1424. 
https://digitalcommons.dartmouth.edu/facoa/1424 
This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has 
been accepted for inclusion in Open Dartmouth: Published works by Dartmouth faculty by an authorized 
administrator of Dartmouth Digital Commons. For more information, please contact 
dartmouthdigitalcommons@groups.dartmouth.edu. 
Authors 
Yan Ma, Steven Fiering, Candice Black, Xi Liu, Ziqiang Yuan, Vincent A. Memoli, David J. Robbins, Heather 
A. Bentley, Gregory J. Tsongalis, Eugene Demidenko, Sarah J. Freemantle, and Ethan Dmitrovsky 
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/1424 
Transgenic cyclin E triggers dysplasia and multiple
pulmonary adenocarcinomas
Yan Ma*, Steven Fiering†‡, Candice Black‡§, Xi Liu*, Ziqiang Yuan*, Vincent A. Memoli‡§, David J. Robbins*‡,
Heather A. Bentley§, Gregory J. Tsongalis‡§, Eugene Demidenko‡¶, Sarah J. Freemantle*, and Ethan Dmitrovsky*‡**
Departments of *Pharmacology and Toxicology, Medicine, †Microbiology and Immunology, §Pathology, and ¶Biostatistics and Epidemiology, and ‡Norris
Cotton Cancer Center, Dartmouth Medical School, Hanover, NH 03755 and Dartmouth–Hitchcock Medical Center, Lebanon, NH 03756
Edited by William T. Wickner, Dartmouth Medical School, Hanover, NH, and approved December 22, 2006 (received for review August 7, 2006)
Cyclin E is a critical G1-S cell cycle regulator aberrantly expressed in
bronchial premalignancy and lung cancer. Cyclin E expression
negatively affects lung cancer prognosis. Its role in lung carcino-
genesis was explored. Retroviral cyclin E transduction promoted
pulmonary epithelial cell growth, and small interfering RNA tar-
geting of cyclin E repressed this growth. Murine transgenic lines
were engineered to mimic aberrant cyclin E expression in the lung.
Wild-type and proteasome degradation-resistant human cyclin E
transgenic lines were independently driven by the human surfac-
tant C (SP-C) promoter. Chromosome instability (CIN), pulmonary
dysplasia, sonic hedgehog (Shh) pathway activation, adenocarci-
nomas, and metastases occurred. Notably, high expression of
degradation-resistant cyclin E frequently caused dysplasia and
multiple lung adenocarcinomas. Thus, recapitulation of aberrant
cyclin E expression as seen in human premalignant and malignant
lung lesions reproduces in the mouse frequent features of lung
carcinogenesis, including CIN, Shh pathway activation, dysplasia,
single or multiple lung cancers, or presence of metastases. This
article reports unique mouse lung cancer models that replicate
many carcinogenic changes found in patients. These models pro-
vide insights into the carcinogenesis process and implicate cyclin E
as a therapeutic target in the lung.
lung carcinogenesis  lung cancer  sonic hedgehog
Cyclin E binds to and activates cyclin-dependent kinase 2(Cdk2) and promotes G1 cell cycle transition (1, 2). Cyclin
E overexpression shortens the G1 cell cycle, alters S-phase
progression, and causes chromosomal instability (CIN) (3, 4).
Cyclin E has oncogenic potential. Transgenic cyclin E expression
in the mammary gland causes hyperplasia and carcinoma (5).
Aberrant cyclin E expression occurs in premalignant lung lesions
(6). Cyclin E expression has a negative prognostic impact in lung
cancers (7–9). Tobacco carcinogens can transform immortalized
human bronchial epithelial (HBE) cells and augment cyclin E
expression (10). All-trans-retinoic acid (RA) chemoprevention
represses cyclin E and associated Cdk2 kinase activity, causing
G1 arrest (10). This would permit repair of genomic DNA
damage by carcinogens and was proposed as a chemoprevention
mechanism (10, 11).
Regulation of cyclin E is critical for cell cycle progression.
Cyclin E accumulates late in G1 and declines through S phase (1,
2). Cyclin E is regulated by the ubiquitin–proteasome pathway
(12). The ubiquitin ligase Cullin 3 promotes ubiquitination of
free cyclin E not bound to Cdk2 (13). Ubiquitination of Cdk2-
bound cyclin E depends on phosphorylation of threonines
Thr-62 and -380 as well as Ser-372 and -384 (14–16). Phosphor-
ylation of these residues allows cyclin E to be recognized by Fbw7
(hCdc4) (15, 17, 18), a phosphoepitope-specific substrate rec-
ognition component of the Skp1-Cullin1 F-box protein (SCF)
ubiquitin ligase. Fbw7 mutations occur in malignancies and
contribute to cell cycle deregulation (15, 18–21). Mutations of
residues 62 and/or 380 stabilize cyclin E (14, 15, 22). Effects of
wild-type (WT) and degradation-resistant (T62A/T380A) trans-
genic cyclin E expression were examined in this study. Notably,
transgenic cyclin E recapitulates in the mouse many features of
human lung carcinogenesis including CIN, sonic hedgehog (Shh)
pathway activation, pulmonary dysplasia, single or multiple lung
adenocarcinomas, and presence of metastases. The therapeutic
implications of these findings are discussed.
Results
siRNA Targeting of Cyclin E. Targeting cyclin E with siRNAs
repressed HBE cell growth. This targeting reduced cyclin E
protein expression by 75% as compared with controls (Fig. 1A)
and caused significant growth suppression (P  0.0001; Fig. 1 A).
A second siRNA targeting a different cyclin E domain con-
firmed these results, and mock transfection did not appreciably
affect cyclin E expression (data not shown).
Cyclin E Transduction. Exogenous cyclin E expression promotes
HBE cell growth (10). To learn whether murine cells were
similarly affected, C10 cells were transduced with a retrovirus
encoding WT or degradation-resistant human cyclin E (hcyclin
E) or an insertless control vector. Expression of degradation-
resistant cyclin E was stabilized relative to WT cyclin E (Fig. 1B).
An anti-cyclin E antibody was used for immunoblot analyses to
identify exogenous human, but not endogenous murine, cyclin E.
WT cyclin E transduced C10 cells increased anchorage inde-
pendent growth relative to controls. An even greater increase
followed transduction of degradation-resistant cyclin E (P 
0.001; Fig. 1B). These findings established a role for cyclin E in
murine pulmonary epithelial cell growth.
Transgenic Cyclin E Expression. To explore cyclin E effects, murine
transgenic lines were engineered to express in the lung WT or
degradation-resistant hcyclin E (T62A/T380A). Transgenes
were each driven by the human surfactant C (SP-C) promoter
(Fig. 2A), which conferred expression in alveolar type II and
bronchioalveolar cells (23). Two independent WT cyclin E and
two independent degradation-resistant cyclin E founder mice
were identified by Southern blot analyses (data not shown).
Transgenic hcyclin E protein was detected by using an immu-
noblot assay with an antibody recognizing hcyclin E protein in all
transgenic lines, but not in nontransgenic (Tg) control mice
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(Fig. 2B). As expected from prior work (24), transgenic proteins
migrated at 47Kd and 37Kd (Fig. 2B). These species were also
present in human lung cancer cell lines A549 and H520 and other
lines (data not shown).
Transgenic cyclin E protein expression was comparable in WT
cyclin E lines 1 and 2 and degradation-resistant cyclin E line 4
(Fig. 2B). The degradation-resistant cyclin E transgenic line 3
had low expression of transgenic protein (Fig. 2B). Immunohis-
tochemical analyses revealed that hcyclin E expression was
detected in nuclei of bronchiole epithelial cells and pneumocytes
of WT cyclin E lines and degradation-resistant cyclin E trans-
genic line 4 (data not shown) but was undetected in the Tg
mouse lung (Fig. 2C). Nuclear localization of exogenous hcyclin
E protein was confirmed (Fig. 2C). Cyclin E immunostaining was
detected in line 3, but fewer cells stained than in other lines (data
not shown).
WT and proteasome-degradation-resistant cyclin E transgenic
mice developed pulmonary premalignancy and malignancy (Fig.
3 A and B). Histopathological analyses revealed dysplasia alone
or with lung adenocarcinoma in affected mice (Fig. 3B). His-
topathologic features of dysplasia were similar to those in clinical
lesions (6). Lung adenocarcinomas in these mice (Fig. 2B)
resembled lesions found in clinical lung cancers (25).
Incidences of dysplasia and lung cancer were each examined
in cyclin E transgenic lines and control Tg mice (Table 1).
Significant sex differences in these incidences were not observed
(P  0.1). Tumors were observed in WT and degradation-
resistant cyclin E transgenic lines as early as 5 months of age.
Most cyclin E transgenic mice were euthanized at 12–14 months
of age for analyses of dysplasia and lung cancer incidence. Mice
Table 1. Incidences of lung cancer, dysplasia, and multiple lung cancers in nontransgenic
control and transgenic mice
Line N
Cancers Dysplasia Multiple cancers
N (%) P N (%) P N (%) P
Tg 48 4 (8.3) — 2 (4.2) — 0 (0) —
Line 1 40 9 (22.5) 0.067 6 (15) 0.082 1 (2.5) 0.37
Line 2 16 9 (56.3) 0.0002 1 (6.3) 0.76 0 (0) 1.0
Line 3 42 7 (16.7) 0.198 4 (9.5) 0.27 1 (2.4) 0.35
Line 4 34 17 (50) 0.0001 11 (32.3) 0.001 7 (20.6) 0.0026
Summary of incidences (number, N, and percentage) of lung cancer, dysplasia, and multiple lung cancers in
nontransgenic (Tg) control mice, WT cyclin E transgenic lines 1 and 2, and degradation-resistant cyclin E
transgenic lines 3 and 4.
Fig. 1. Cyclin E effects on growth of pulmonary epithelial cells. (A) BEAS-2B
cells were independently transiently transfected with cyclin E targeting or
control siRNAs. (Left) Cyclin E protein expression was examined by immuno-
blot analyses 96 h after siRNA transfection. Actin expression served as a
loading control. (Right) Viable cell numbers 96 h after transfection. Mean
values and SDs from three independent experiments are shown. Significant
difference was observed between control and cyclin E targeting siRNAs (P 
0.0001). (B) C10 cells were independently transduced with WT cyclin E, deg-
radation-resistant cyclin E or an insertless control vector. (Left) Exogenous
cyclin E expression was examined by immunoblot analysis. The degradation-
resistant cyclin E species was stabilized. Actin expression served as a loading
control. (Right) Anchorage-independent colonies 75 m in diameter were
scored at 2 weeks.
Fig. 2. Generation of human SP-C (hSP-C) driven WT cyclin E or degradation-
resistant (T62A/T380A) hcyclin E transgenic lines. (A) The cyclin E transgenic
constructs. Restriction endonuclease sites used for cloning these species are
shown. (B) Exogenous hcyclin E immunoblot expression profiles in normal
lung tissues of transgenic mice. Actin expression served as a loading control.
(C) Immunohistochemical detection of hcyclin E in lung tissues of a represen-
tative WT (line 2) transgenic cyclin E mouse and a nontransgenic (Tg) control
mouse that did not stain. The left and right arrows in Right indicate hcyclin E
nuclear staining in representative pneumocyte and bronchiole epithelial cells,
respectively.
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with advanced tumors were euthanized for symptoms of labored
breathing and decreased body weight.
To confirm pulmonary dysplasia and tumors were increased by
transgenic cyclin E expression in the murine FVB/N line, cohorts
of age-matched WT (Tg) control mice were evaluated for
pulmonary dysplasia and lung tumor formation. Of 48 control
mice, only 4 had lung cancers, and 2 others developed pulmonary
dysplasia without cancer. In marked contrast, 18 of 56 transgenic
WT cyclin E mice of lines 1 and 2 in this age range had lung
adenocarcinomas. Six of them developed both pulmonary dys-
plasia and adenocarcinoma, and one mouse had dysplasia with-
out adenocarcinoma. Seventeen of 34 degradation-resistant cy-
clin E transgenic line 4 mice developed lung adenocarcinomas,
and 8 of these mice developed both pulmonary dysplasia and
adenocarcinoma. Three other mice had pulmonary dysplasia
without lung adenocarcinoma. Seven of 42 degradation-resistant
cyclin E transgenic line 3 mice developed lung adenocarcinoma.
WT cyclin E transgenic lines 1 and 2 had increased incidence of
dysplasia as compared with control mice, but this was not
statistically significant (Table 1). Of WT cyclin E transgenic
mice, 22.5% (line 1) and 56.3% (line 2) had lung cancers as
compared with 8.3% of Tg control mice (Table 1). The
degradation-resistant cyclin E transgenic line 4 displayed a
substantially higher incidence of dysplasia than control mice
(32.3% vs. 4.2%). This difference was significant (P  0.001;
Table 1).
Half of degradation-resistant cyclin E transgenic line 4 mice
developed lung cancers (Table 1). Cancer incidence between line
4 and control mice was significantly different (P  0.0001).
Degradation-resistant cyclin E line 3 had much lower transgenic
cyclin E expression relative to line 4 (Fig. 2B). Incidence of
dysplasia in line 3 was higher than in control mice (9.5% vs.
4.2%) but was not statistically significant (Table 1). Similar
results were observed for incidence of lung cancers (16.7% vs.
8.3%; Table 1). Dysplasia and lung cancer incidences for cyclin
E lines 3 and 4 were statistically different (P  0.013 and 0.001,
respectively). Dysplasia incidence was highest in degradation-
resistant cyclin E line 4 (32.3%) and was significantly different
compared with control mice (P  0.001). All of the cyclin E
transgenic lines had increased dysplasia and lung cancer com-
pared with Tg controls.
Multiple lung cancer incidences were examined. All Tg
control mice with lung cancer had a single tumor (Table 1); only
2.5% (line 1) WT cyclin E transgenic mice and 2.4% (line 3)
degradation-resistant cyclin E transgenic mice developed two
lung cancers (Table 1). Strikingly, 20.6% of degradation-
resistant cyclin E transgenic line 4 mice developed at least two
lung adenocarcinomas (Table 1). Line 4 displayed a significant
increase in incidence of multiple lung cancers relative to Tg
mice (P  0.0026). Metastases to pleura, pulmonary lymph
nodes or thymus were detected in lines 1 (one mouse), 2 (one
mouse), and 4 (three mice). An example of a thymic metastasis
appears in Fig. 3E. Metastases were not detected in Tg mice.
The presence of increased transgenic cyclin E immunohisto-
chemical expression in dysplastic and malignant lung relative to
normal lung tissues implicated cyclin E involvement in murine
lung carcinogenesis (Fig. 3C and data not shown). The Ki-67
immunohistochemical proliferation marker was readily detected
in dysplasia and lung cancers from degradation-resistant cyclin
E transgenic line 4 vs. normal lungs of Tg control mice (Fig.
3D). Similar histopathology, hcyclin E and Ki-67 immunohisto-
chemical expression profiles were detected in dysplastic and
malignant lung lesions from WT cyclin E transgenic mice (data
not shown).
Cyclin E expression causes genomic instability as does cyclin
E stabilization through an alanine transversion of residue 380
(T380A) (4). This increased associated kinase activity and CIN
(4). The degradation-resistant transgenic cyclin E species stud-
ied here is reported as more stable than cyclin E T380A (15).
CIN was examined in lung cancers of WT and degradation-
resistant cyclin E transgenic mice by FISH analyses using
chromosome 4 and 6 probes. Aneuploidy of these chromosomes
was frequently observed in lung adenocarcinoma lines (26).
Fig. 3. Pathology and immunohistochemical expression of hcyclin E in
transgenic lines. (A) Lungs from representative nontransgenic (Tg) control
(Left), WT cyclin E (line 2, Center), and degradation-resistant cyclin E (line 4,
Right) transgenic mice are shown. Independent lung tumors are indicated by
arrows. (B) Hematoxylin/eosin staining of lung tissue sections. Histopatholog-
ically normal lung tissue (Left) from a representative Tg control mouse and
dysplasia (Center) and adenocarcinoma (Right) from a representative degra-
dation-resistant transgenic cyclin E line 4 mouse are shown. (C) Immunohis-
tochemical detection of hcyclin E in dysplastic and malignant lung lesions from
the same degradation-resistant cyclin E transgenic mouse in B. Arrow indicates
hcyclin E nuclear staining in a cell from a dysplastic lesion. (D) Immunohisto-
chemical detection of Ki-67 in a representative Tg control mouse and the
same lung lesions from the cyclin E line in B. (E) A representative metastasis
(arrow depicts thymic metastasis) present in WT cyclin E transgenic line 2 is
shown.











Aneuploid cells for each of these chromosome markers were
prominent in lung cancers from transgenic cyclin E mice relative
to adjacent normal lung tissues. This degree of aneuploidy was
not seen in normal or malignant lung tissues from Tg control
mice (Table 2).
Hedgehog (Hh) Pathway Activation. Not all cyclin E transgenic mice
developed pulmonary dysplasia or malignancy. This indicated
that cyclin E likely cooperated with other genetic alterations in
lung carcinogenesis. Aberrant Hh signaling occurs in many
cancers, including lung cancers (27–29). Whether this pathway
was activated in dysplasia or lung cancer from cyclin E transgenic
mice was examined by immunoblot analyses (Fig. 4A). Shh was
overexpressed in seven of eight examined lung cancers from WT
cyclin E transgenic mice (data not shown) and five of six lung
tumors from degradation-resistant transgenic cyclin E mice, as
compared with normal lung tissues from the same transgenic or
control mice (Fig. 4A). Gli1, an Hh pathway transcriptional
target (27), was overexpressed in four of eight examined WT
transgenic cyclin E lung cancers and four of six lung cancers from
degradation-resistant transgenic cyclin E mice (Fig. 4A and data
not shown), relative to normal lung tissues from the same
transgenic mice. Normal lungs from age- and sex-matched
nontransgenic mice, WT cyclin E, and degradation-resistant
cyclin E transgenic mice without evidence of lung adenocarci-
nomas were found to have low or undetected Shh and Gli1
protein expression (Fig. 4A and data not shown). Gli1 and Shh
were often coexpressed in these tumors (Fig. 4A and data not
shown). Of five examined cancers from degradation-resistant
cyclin E transgenic mice, four had both Gli1 and Shh overex-
pression, and one had only Shh overexpression. These findings
were confirmed by an immunohistochemical assay (Fig. 4B)
establishing that activation of Gli1 expression occurs within
dysplastic and malignant lung lesions of transgenic cyclin E mice.
Whether cyclin E overexpression activated the Shh pathway in
C10 cells was examined. RT-PCR assays were used to detect Shh
pathway members Smoothened (Smo), Gli1, and Patched 1
(Ptch1) in C10 cells transduced with WT or degradation-
resistant hcyclin E. Findings were compared with insertless
vector-transduced C10 cells. An increase in mRNA expression
for Smo, Gli1, and Ptch1 was observed after exogenous cyclin E
expression. Smo activates the Hh pathway through the Gli1
transcription factor (27). Ptch1, a transmembrane receptor,
when bound to Hh ligands, blocks Smo function (27). Both Ptch1
and Gli1 are transcriptional targets of Hh signaling (27). Ex-
pression for Smo, Gli1, and Ptch1 increased in C10 cells trans-
duced with WT or degradation-resistant hcyclin E, relative to
controls (see supporting information (SI) Fig. 5). Shh mRNA
was undetected in these cells.
Whether results from these transgenic models predicted find-
ings in clinical lung carcinogenesis was examined. A series of 101
lung cancer cases (including 45 adenocarcinomas) revealed that
90% of these cases had Gli1 immunostaining (29). Nine of
these lung cancers and adjacent normal lung were immuno-
stained for hcyclin E with the same antibody used in analyses of
these transgenic lines. Each case overexpressed cyclin E relative
to adjacent normal lung tissues (data not shown). Studies were
extended to the premalignant lesion, adenomatous hyperplasia.
A representative lesion was independently immunostained for
cyclin E and Gli1; both species were detected in Fig. 4C.
Discussion
Cyclin E, an important cell cycle regulator, is deregulated in
pulmonary dysplasia and malignancy; it confers a poor prognosis
in lung cancer (1–4, 6–9). Findings reported here reveal retro-
viral transduction of cyclin E promoted growth of pulmonary
epithelial cells; targeting cyclin E expression had the opposite
Table 2. FISH analyses on paired lung cancers and normal lung
tissues from nontransgenic and transgenic lines
Line Tissue
Chromosome 4 Chromosome 6
N 2, % N 2, %
Tg-1 Cancer 100 0 25 0
Normal 157 0 75 0
Tg-2 Cancer 50 0 50 2
Normal 160 0 150 0
Line 2 Cancer 85 100 143 88.8
Normal 100 0 50 0
Line 2 Cancer 100 27 176 91.5
Normal 250 0 55 9.1
Line 4 Cancer 188 86.2 91 78
Normal 100 1 50 0
Line 4 Cancer 150 100 100 100
Normal 241 0 125 0
The FISH analyses independently performed by using chromosome 4 and 6
probes on paired lung cancers (cancer) and normal lung (normal) tissues from
two different nontransgenic (Tg-1 and Tg-2) mice and different transgenic
lines (line 2, WT cyclin E and line 4, degradation-resistant cyclin E). The number
(N) and percentage (%) are displayed. Findings reveal that CIN prominently
occurs in transgenic cyclin E lung cancers but not in normal lung tissues of
transgenic and Tg mice or in lung cancers arising in Tg mice.
Fig. 4. Activation of the Shh pathway in cyclin E transgenic mice and
comparison with human adenomatous hyperplasia. (A) Shh, Gli1, and actin
immunoblot expression profiles in lung tissues from Tg (control), WT trans-
genic cyclin E (data not shown), and degradation-resistant transgenic cyclin E
mice. Two representative age- and sex-matched groups are shown. Lanes 1
and 7, normal (N) lung tissues from Tg control mice; lanes 2 and 8, normal (N)
lung tissues from transgenic cyclin E line 4 mice; lanes 3 and 4, a pair (depicted
by line) of normal (N) lung and malignant (T) lung tissues of a representative
transgenic cyclin E line 4 mouse. Comparisons appear for paired specimens
from other transgenic cyclin E line 4 mice in lanes 5 and 6 and in lanes 9 and
10. Shh and Gli1 immunoblot expression was observed in malignant lung
tissues from WT transgenic cyclin E lines (data not shown). Actin expression
served as a loading control. (B) Gli1 findings in B were independently con-
firmed by a Gli1 immunohistochemical assay on tissues from WT and degra-
dation-resistant (data not shown) cyclin E transgenic lines. Increased Gli1
expression (relative to normal lung) appears in dysplasia and lung adenocar-
cinoma from the depicted cyclin E transgenic line 2. (C) Immunohistochemical
detection of cyclin E (Left) and Gli1 (Right) in a human adenomatous hyper-
plasia lesion.
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effect (Fig. 1). Murine transgenic lines driven by the SP-C
promoter expressed WT or proteasome-degradation-resistant
cyclin E species. These lines exhibited CIN, pulmonary dysplasia,
single or multiple lung adenocarcinomas, Shh pathway activa-
tion, and presence of metastases (Tables 1 and 2 and Figs. 3 and
4). Incidences of dysplasia and multiple lung cancers were
highest in degradation-resistant cyclin E line 4, as shown in Figs.
3 and 4 and Tables 1 and 2. Aberrant expression for both cyclin
E and the Shh target gene Gli1 were found in dysplastic and
malignant transgenic lung tissues. This provided a basis to search
for and find similar expression patterns in human premalignant
(Fig. 4C) and malignant lung tissues (data not shown).
Lung cancer is the leading cause of cancer mortality for men
and women (30). There is a need to develop transgenic lines that
mimic key features of clinical lung carcinogenesis to better
understand lung cancer biology and molecular therapeutics. This
study was undertaken to reproduce in the mouse lung aberrant
cyclin E expression. This is frequently found in human prema-
lignant and malignant lung lesions; this study confirmed and
extended prior work (6). This carcinogenesis program occurred
without exposure of mice to a tobacco carcinogen. Multiple
genetic changes exist in human lung cancers (30). CIN was
hypothesized to confer other carcinogenic events such as Shh
pathway activation as in lung cancers (27–29).
Findings observed in engineered lung cancer models provide
a rationale to search for similar changes in human lung carci-
nogenesis. This was the case for these new transgenic cyclin E
lines that exhibited CIN as well as Gli1 activation in dysplastic
and malignant lung. Single and multiple lung cancers arose with
kinetics consistent to that seen in the clinic. These transgenic
lung lesions also had histopathology similar to those found in
patients (6). Other genetically engineered mouse lung cancer
models exist, involving p53, ras, c-raf1, RON receptor tyrosine
kinase, and other alterations, as reviewed in ref. 31. The
transgenic lines described in this study are distinct from prior
models because these have reproduced in the mouse a frequent
single genetic change found in human premalignant and malig-
nant lung lesions, aberrant cyclin E expression. This causes CIN,
Shh pathway activation, dysplasia, and individual or multiple
lung cancers. Metastasis is not routinely reported in transgenic
mice (31) but occurs in human lung cancers. This was detected
in some transgenic cyclin E lines. In contrast to prior transgenic
models, these transgenic cyclin E lines reproduce many features
of human lung carcinogenesis. These lines thus are useful tools
to explore the biology of lung cancer.
These transgenic findings implicate cyclin E as an important
regulator of lung carcinogenesis. What needs to be learned is
whether cyclin E is a molecular therapeutic target in the lung.
Future work will determine whether these models are useful to
assess efficacy of antineoplastic agents affecting cyclin E or other
oncogenic targets in lung cancer. That work will be aided by
preliminary findings showing that MRI can detect transgenic
cyclin E tumors (data not shown). Preclinical studies would help
prioritize clinical testing of antineoplastic agents. Treatment of
these transgenic lines with cyclin E targeting agents would
establish whether persistent cyclin E expression or activity is
required for maintenance or progression of dysplastic or malig-
nant lung lesions. Future studies could uncover stem cell pro-
genitors for these transgenic lung tumors and pathways in
addition to the Hh pathway that cooperate with cyclin E to form
lung cancers. Given the high incidence of dysplasia in transgenic
line 4 mice, this line would be a useful model for future
chemoprevention studies.
In summary, findings reported here establish a role for cyclin
E in lung carcinogenesis. Cyclin E transgenic lines reproduce in
the mouse many features of human lung carcinogenesis, includ-
ing CIN, Hh pathway activation, dysplasia, single or multiple
lung adenocarcinomas, and even metastases. Inhibition of cyclin
E proteasome degradation enhanced neoplastic changes in
transgenic lines. The precise mechanism responsible for cyclin E
recapitulating these aspects of lung carcinogenesis needs to be
discerned. This insight would provide a basis for targeting cyclin
E to confer therapeutic or chemopreventive effects in the lung.
Materials and Methods
Cell Culture and Recombinant Plasmids. BEAS-2B immortalized
HBE cells were cultured in serum-free LHC-9 medium (Bioflu-
ids, Rockville, MD) as described (32). Nontumorigenic murine
C10 alveolar type II epithelial cells (33) were cultured in CMRL
1066 medium (Life Technologies, Grand Island, NY) supple-
mented with 10% FBS, 2 mM L-glutamine, 100 units/ml peni-
cillin, and 100 g/ml streptomycin. The GP2-293 packaging cell
line was purchased from BD Bioscience Clontech (Palo Alto,
CA) and cultured in DMEM (BD Bioscience Clontech). Cell
lines were cultured at 37°C in a humidified incubator with 5%
CO2. The pVSV-G expression vector was purchased from BD
Bioscience Clontech. Full-length cDNAs for myc-tagged human
WT and degradation-resistant (T62A/T380A) cyclin E were each
engineered by DraI/EcoRV restriction endonuclease digestions
of respective cyclin E plasmids (11) and independently ligated
into the HpaI restriction site of the pMSCVhyg retroviral vector
(BD Bioscience Clontech).
Plasmid Transfection and Retrovirus Infection. The pMSCVhyg,
pMSCVhyg-myc-cyclin E, and pMSCVhyg-myc-T62A/T380A cy-
clin E retroviral vectors were independently cotransfected with
pVSV-G into GP2–293 cells using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) and manufacturer’s techniques. Two
days after transfection, medium were independently used for
C10 cell viral transductions. Transductants were selected with
hygromycin B (Sigma, St. Louis, MO).
siRNA Experiments. An siRNA was synthesized (Qiagen, Valencia,
CA) and designed to target the hcyclin E coding region with the
sequence 5-AAGTGCTACTGCCGCAGTATC-3. The GL2
siRNA (Dharmacon, Lafayette, CO) served as a control. Trans-
fection was performed as described (32). Viable BEAS-2B cells
were measured by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) assay (34). Three independent tripli-
cate experiments were performed. A second cyclin E siRNA
targeted a different cyclin E coding region: 5-CAGTGGTGC-
GACATAGAGAAC-3.
Anchorage-Independent Clonal Growth Assay. Anchorage-indepen-
dent clonal growth assays were performed as described (35) with
5  104 C10 cells plated onto each well of a six-well plate.
Colonies 75 m in size were scored in three independent
triplicate experiments, with results pooled.
Cyclin E Transgenic Lines. Human SP-C driven untagged WT and
degradation-resistant hcyclin E (T62A/T380A) cDNAs were
independently engineered by EcoRI and HindIII restriction
endonuclease digestions of respective cyclin E plasmids (11)
before insertion into the SP-C-3.7-SV40 vector. For microinjec-
tion, cyclin E constructs were each digested by NedI/NotI
restriction endonucleases and agarose gel purified. Transgenic
lines were engineered in FVB/N mice (The Jackson Laboratory,
Bar Harbor, ME) using established techniques (36). Transgenic
integration was confirmed by Southern blot analyses (37) of
genomic DNA from tails of individual mice. Mice were screened
for the transgene by using a PCR assay (data not shown) (32).
Histopathology and Immunohistochemistry. Lung tissues were for-
malin-fixed, sectioned, and processed for immunostaining by
using standard techniques (25). Tissues were incubated with a
murine monoclonal anti-cyclin E antibody recognizing hcyclin E











protein (HE-12; Neomarkers, Fremont, CA), a rabbit monoclo-
nal Ki-67 antibody (Vector Laboratories, Burlingame, CA), or a
rabbit polyclonal anti-Gli1 antibody (Abcam, Cambridge, MA).
Hematoxylin counterstaining was used. Control tissues stained
appropriately. Analyses were performed by a pathologist who
was unaware of whether tissues were transgenic.
Immunoblot Analyses. Protein extracts were isolated for immuno-
blot analyses by using established techniques (32). Independent
primary antibodies included a murine monoclonal antibody
recognizing hcyclin E (HE-12; Santa Cruz Biotechnology, Santa
Cruz, CA), goat polyclonal antibody recognizing actin (C11;
Santa Cruz Biotechnology), rabbit polyclonal antibodies for Shh
(H-160; Santa Cruz Biotechnology), and Gli1 (Abcam). Anti-
murine and anti-rabbit antisera were purchased from Amersham
Biosciences (Piscataway, NJ), and anti-goat antisera were pur-
chased from Santa Cruz Biotechnology.
FISH. FISH analyses were performed by using paraffin-embedded
tissue sections from transgenic cyclin E and control mice ac-
cording to the manufacturer’s methods (Cambio, Cambridge,
U.K.). Murine chromosome 4 and 6 specific probes were pur-
chased (Cambio) and independently analyzed.
Statistical Analyses. Retroviral transduction and siRNA growth
assays were expressed as mean  SD. A two-sided test on
proportion for group comparison (38) was used for analyses of
dysplasia and single or multiple lung tumors with the S-Plus 6.1
statistical package (Insightful Inc., Seattle, WA). Statistical
significance was considered for P  0.05.
RT-PCR Assays. Total cellular RNA was isolated by using the
RNeasy Protect Mini Kit (Qiagen) or TRI Reagent (Molecular
Research Center, Cincinnati, OH). Contaminating DNA was
removed by using a DNA-free kit (Ambion, Austin, TX).
RT-PCR assays were performed by using established methods
(32) with the following primers: Smo forward, 5-AGATTGTT-
TGCCGAGCAGAT-3, and reverse, 5-GTGAGGACAAA-
GGGGAGTGA-3; Gli1 forward, 5-CCTGGTGGCTTTCAT-
CAACT-3, and reverse, 5-GCTAGACATGTCCCCTTCCA-
3; Ptch1 forward, 5-TACGTGGAGGTGGTTCATCA-3, and
reverse, 5-CCTGAGTTGTCGCAGCATTA-3; GAPDH for-
ward, 5-AACTTTGGCATTGTGGAAGG-3, and reverse,
5-ACACATTGGGGGTAGGAACA-3; and Shh forward, 5-
TTAAATGCCTTGGCCATCTC-3, and reverse, 5-CCACG-
GAGTTCTCTGCTTTC-3.
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